Maze Therapeutics GAAP EPS of -$0.77 misses by $0.09

* Maze Therapeutics press release [https://seekingalpha.com/pr/20198560-maze-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights] (NASDAQ:MAZE [https://seekingalpha.com/symbol/MAZE]): Q2 GAAP EPS of -$0.77 misses by $0.09.
* Cash and cash equivalents were $264.5 million as of June 30, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash and cash equivalents will fund operations into the second half of 2027.

MORE ON MAZE THERAPEUTICS

* Historical earnings data for Maze Therapeutics [https://seekingalpha.com/symbol/MAZE/earnings]
* Financial information for Maze Therapeutics [https://seekingalpha.com/symbol/MAZE/income-statement]